The Pharma Data

JANUARY 4, 2021

05, 2021 (GLOBE NEWSWIRE) — Polyphor AG (SIX: POLN) announced today that Gökhan Batur, Chief Executive Officer, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Thursday, January 7 from 8:00AM Eastern Standard Time. Investors can pre-register for the event here.

Clinical Development 52

Clinical Development Trials Treatment Research 52

Drug Discovery World

AUGUST 22, 2023

Bloom Science has announced positive topline data from a Phase I clinical trial of BL-001 , a potential first-in-class therapeutic the company is developing for Dravet syndrome and amyotrophic lateral sclerosis (ALS). BL-001 shows promise as a novel treatment option that can change lives.

Trials 130

Trials Clinical Trials Science Clinical Development 130

The Pharma Data

FEBRUARY 24, 2022

“Despite treatment with standard of care, the residual risk for cardiorenal events remains high in patients living with chronic kidney disease and type 2 diabetes. Up to 40% of all patients with type 2 diabetes (T2D) develop CKD. It is estimated that CKD affects more than 160 million people with T2D worldwide.

Clinical Development 52

Clinical Development Disease Therapies Treatment 52

Drug Discovery World

OCTOBER 2, 2023

DDW’s Megan Thomas heard from attendees about their key takeaways from the event. Dr Mindy Miller, Lead Research Scientist, Terumo Blood And Cell Technologies Conversations and data shared at the CAR-TCR 8 th Annual Summit highlighted the importance of optimising the science behind the therapies to broaden patient access.

Therapies 264

Therapies Treatment Hospitals Production 264

Drug Discovery World

APRIL 25, 2023

“We have reached an important milestone with the dosing of the second participant in our clinical trial evaluating a potentially groundbreaking CAR-T cell therapy to cure HIV,” said Mehrdad Abedi, Professor of Internal Medicine, Hematology and Oncology and co-investigator of the study. “So

Research 130

Research Clinical Trials Therapies Clinical Development 130

The Pharma Data

MAY 2, 2021

Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. About Sandoz.

Biosimilars 40

Biosimilars Clinical Development Production Government 40

Drug Discovery World

JUNE 21, 2023

Moreover, there were no reported significant adverse events and CITI-002 was well tolerated by patients in the study. The company has stated its intention to schedule an end of Phase II meeting with the US Food and Drug Administration (FDA) to begin planning the next steps in the regulatory and clinical development programme for CITI-002.

Trials 130

Trials Treatment Clinical Trials Clinical Development 130

The Pharma Data

OCTOBER 21, 2020

and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme.

Clinical Development 52

Clinical Development Therapies Clinical Trials FDA Approval 52

Drug Discovery World

NOVEMBER 10, 2023

KIO-301 was safe and well tolerated with no ocular and non-ocular serious adverse events, nor any signs of retinal inflammation. The mechanism of action and trial data firmly support KIO-301’s continued development, potentially filling a major unmet need in the search for treatments for these patients,” said Dr Van Gelder.

Clinical Trials 130

Clinical Trials Small Molecule Trials Clinical Development 130

Drug Discovery World

MAY 3, 2023

Official comments “Measuring endothelial dysfunction with the EndoPAT technology in drug trials is a cost-effective and robust method for early documentation of proof-of-concept in pulmonary, renal and vascular diseases” says Elin Rosendahl, VP Clinical Operations, Vicore Pharma.

FDA Approval 130

FDA Approval Trials Pharmaceutical Companies Disease 130

Drug Discovery World

JULY 3, 2023

This was centred around pre-clinical models (in vitro and in vivo) to support discovery and development, re-entering the fray with costimulatory agonists, and clinical development strategies for combinations with immune cell engagers​.

Engineering 130

Engineering Virus Therapies Treatment 130

Drug Discovery World

OCTOBER 24, 2023

One of the key presentations will be given by Dr Qasim Ahmad, Chief Medical Officer of IO Biotech, a Clinical Oncologist with two decades of strategic clinical development, medical affairs, and marketing authorisation expertise.

Vaccine 130

Vaccine Research Clinical Development Science 130

The Pharma Data

NOVEMBER 11, 2021

The primary efficacity endpoint is the time to first event of cardiovascular death or hospitalization for heart failure (NCT05093933). Joerg Koglin, vice chairman, Global Clinical Development and Therapeutic Area Head, Cardiovascular for Merck Research Laboratories. Reclamation for the VICTOR trial has begun. each time,” saidDr.

Clinical Trials 40

Clinical Trials Hospitals Trials Research Laboratories 40

Drug Discovery World

SEPTEMBER 12, 2022

Chaired by Karin Blumer, Director of Global Patient Engagement at Novartis, the first event in this track, called ‘Patient Engagement: Driving Patient Advocacy to Inform Patient Centric Development’, looked into the multi-layered importance of involving patients in the drug development process, particularly in this case for gene therapy.

Clinical Trials 130

Clinical Trials Trials Therapies Science 130

Drug Discovery World

MARCH 13, 2024

of patients experienced adverse events (AEs), with no evidence of dose-dependent increase in AEs, including gastrointestinal disorders. The most frequently reported AEs were nasopharyngitis (18.1%), upper respiratory tract infection (9.7%) and Covid-19 (5.3%). Across JNJ-2113 treatment groups, 58.6%

Trials 130

Trials Clinical Trials Treatment Licensing 130

Alta Sciences

AUGUST 18, 2023

Don’t miss out: [link] Event End Date Thu, 10/26/2023 - 12:00 Event Start Date Thu, 10/26/2023 - 12:00 Weight 1

Drug Development 40

Drug Development Compliance Clinical Development FDA 40

Drug Discovery World

JUNE 5, 2023

DDW’s Megan Thomas comments on the event. New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk.

Small Molecule 130

Small Molecule Treatment Science Disease 130

The Open Targets Blog

JUNE 26, 2023

Gene essentiality Core essential genes are unlikely to tolerate inhibition, and are therefore susceptible to cause adverse events if modulated. This is crucial safety information for drug discovery scientists looking to develop inhibition strategies. Users can view a specific list of adverse events, mapped to EFO terms.

Disease 59

Disease Clinical Development Clinical Trials Production 59

The Pharma Data

MARCH 28, 2022

Dupixent peak sales ambition raised to more than €13 billion Chronic obstructive pulmonary disease 2023 pivotal readouts provide potential for additional Dupixent sales ambition upgrade 13 potential new medicines currently in the clinic to treat chronic inflammatory diseases, with 17 readouts expected by the end of 2024. CEST / 8 a.m.

Small Molecule 52

Small Molecule Clinical Development Disease Science 52

Drug Discovery World

APRIL 3, 2024

million from the Spanish Research Agency (AEI), under the call for grants for Public-Private Collaboration Projects, to accelerate the development of an innovative treatment aimed at controlling disabling and lethal haemorrhage.

Therapies 130

Therapies Laboratories Pharmacokinetics Treatment 130

Conversations in Drug Development Trends

APRIL 5, 2024

Each day throughout the month of February, we heard what was on the minds and hearts of patients and patient advocacy organizations, clinical developers driving treatments, and family members supporting people with rare diseases. We were overwhelmed by how excited the community was to participate!

Disease 52

Disease Clinical Trials Trials Treatment 52

The Pharma Data

SEPTEMBER 16, 2020

executive vice president of Research and Development at Amgen, along with members of Amgen’s clinical development team and clinical investigators, will discuss Phase 1 data being presented on the Company’s investigational KRAS G12C inhibitor sotorasib (AMG 510). Reese , M.D., On Monday, Sept. PDT , David M.

Clinical Development 52

Clinical Development Therapies Disease Research 52

The Pharma Data

MARCH 28, 2022

Further, Ozempic ® is indicated to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease. The most common adverse events were gastrointestinal. mg, the gastrointestinal adverse events were similar for semaglutide 2.0 mg and 2.0 Ozempic ® 2.0

Treatment 52

Treatment FDA Approval FDA Trials 52

The Pharma Data

APRIL 24, 2023

“We are continuing to work with the FDA to facilitate completion of their review of the quizartinib new drug application in order to bring this important medicine to patients as soon as possible,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo.

FDA 40

FDA Clinical Development Trials Treatment 40

The Pharma Data

JUNE 7, 2023

Grade 3 or greater treatment-related adverse events (TRAEs) occurred in 31% of patients receiving doublet therapy and 58% of patients receiving triplet therapy. Across treatment cohorts, there were 27 interstitial lung disease (ILD) or pneumonitis events adjudicated as drug-related by an independent committee.

Trials 40

Trials Protein Expression Therapies Treatment 40

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Collaborations.

Drugs 130

Drugs Therapies Clinical Trials Cell Based Assays 130

The Pharma Data

OCTOBER 26, 2020

Participants may access the live webcast via a link on the Synlogic website in the Events Calendar of the Investors and Media section. The forward-looking statements contained in this press release reflect Synlogic’s current views with respect to future events. The conference ID number for the call is 8557525.

Clinical Trials 52

Clinical Trials Clinical Development Trials Engineering 52

Advarra

FEBRUARY 24, 2023

But what does “working” really mean when efficacy means something subjective, like quality of life, reduced psychiatric events, or less symptoms? Also known as a clinical event committee (CEC), EAC members evaluate a clinical event in the context of the protocol and the individual participant’s medical information.

Clinical Trials 52

Clinical Trials Trials FDA Therapies 52

The Pharma Data

APRIL 28, 2022

In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec. The rates of severe or clinically significant hypoglycaemia (blood glucose below 3 mmol/L) were 0.73 events per patient-year exposed to insulin degludec.

Trials 52

Trials Clinical Trials Treatment Clinical Development 52

Drug Discovery World

SEPTEMBER 14, 2023

joined Pfizer’s Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President reporting to Chairman and Chief Executive Officer, Albert Bourla. Chris Boshoff, M.D.,

Vaccine 147

Vaccine FDA Approval Drugs Licensing 147

The Premier Consulting Blog

OCTOBER 11, 2022

However, acceptance of that data depends on a sponsor’s understanding of the FDA criteria for historical control groups, study data standards, and clinical meaningfulness. In this article, we review two case studies involving the successful use of RWD or RWE in advancing the clinical development of treatments for rare diseases.

Disease 52

Disease FDA FDA Approval Regulations 52

The Pharma Data

OCTOBER 15, 2020

ASLAN believes ASLAN003 has the potential to bethe most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH enzyme than teriflunomide. SINGAPORE, Oct. The company expects to share further details in early 2021.

Pharmaceuticals 40

Pharmaceuticals Cell Based Assays Clinical Development Treatment 40

The Pharma Data

JUNE 7, 2023

Rubin, senior vice president, global clinical development, Merck Research Laboratories. The number of patients reporting treatment related Grade ≥ 3 adverse events were similar between the arms (25% vs 18%, respectively). The safety profile of KEYTRUDA was consistent with findings from previous studies.

Clinical Trials 40

Clinical Trials Therapies Research Laboratories Vaccine 40

Agency IQ

DECEMBER 1, 2023

What we expect European regulators to do in December 2023 In this new recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more. Upcoming E.U.

Regulations 40

Regulations Clinical Trials Production Biosimilars 40

The Pharma Data

FEBRUARY 13, 2022

Asundexian is currently in Phase II clinical trials in all three indications either as a standalone therapy, or in combination with anti-platelet therapy. Inhibition of FXIa by asundexian is hypothesized to provide protection from thrombotic events without increasing the risk of bleeding.

FDA 40

FDA Clinical Trials Trials Therapies 40

The Pharma Data

DECEMBER 29, 2020

The expansion of the eligible stocks of Hong Kong Stock Connect, will further optimize the interconnected, intercommunicated, and mutual development of the capital markets between Mainland China and Hong Kong. ” About Ascentage Pharma.

FDA 52

FDA Clinical Development Regulations Clinical Trials 52

The Pharma Data

DECEMBER 23, 2020

The Company has Now Resumed the Clinical Development of its Proposed Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum. With this funding now complete, the Company is excited about its prospects for 2021 – as it pertains to its pharmaceutical development efforts. . NEW YORK, NY, Dec. Contact: Tauriga Sciences, Inc.

Science 52

Science Pharmaceuticals Clinical Development Production 52